1.AMPA receptor agonists: resolution, configurational assignment, and pharmacology of (+)-(S)- and (-)-(R)-2-amino-3-[3-hydroxy-5-(2-pyridyl)-isoxazol-4-yl]-propionic acid (2-Py-AMPA).
Johansen TN1, Ebert B, Falch E, Krogsgaard-Larsen P. Chirality. 1997;9(3):274-80.
We have previously shown that whereas (RS)-2-amino-3-(3-hydroxy-5-phenylisoxazol-4-yl)propionic acid (APPA) shows the characteristics of a partial agonist at (RS)-2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)propionic acid (AMPA) receptors, (S)-APPA is a full AMPA receptor agonist and (R)-APPA a weak competitive AMPA receptor antagonist. This observation led us to introduce the new pharmacological concept, functional partial agonism. Recently we have shown that the 2-pyridyl analogue of APPA, (RS)-2-amino-3-[3-hydroxy-5-(2-pyridyl)isoxazol-4-yl]propionic acid (2-Py-AMPA), is a potent and apparently full AMPA receptor agonist, and this compound has now been resolved into (+)- and (-)-2-Py-AMPA (ee > or = 99.0%) by chiral HPLC using a Chirobiotic T column. The absolute stereochemistry of the enantiomers of APPA has previously been established by X-ray analysis, and on the basis of comparative studies of the circular dichroism spectra of the enantiomers of APPA and 2-Py-AMPA, (+)- and (-)-2-Py-AMPA were assigned the (S)- and (R)-configuration, respectively.
2.Synthesis, photophysical and electrochemical properties, and biological labeling studies of cyclometalated iridium(III) bis(pyridylbenzaldehyde) complexes: novel luminescent cross-linkers for biomolecules.
Lo KK1, Chung CK, Zhu N. Chemistry. 2003 Jan 20;9(2):475-83.
We report the synthesis, characterization, photophysical, and electrochemical properties of a series of luminescent cyclometalated iridium(III) complexes containing two aldehyde functional groups [Ir(pba)(2)(N-N)](PF(6)) (Hpba=4-(2-pyridyl)benzaldehyde; N-N=2,2'-bipyridine, bpy (1), 1,10-phenanthroline, phen (2), 3,4,7,8-tetramethyl-1,10-phenanthroline, 3,4,7,8-Me(4)-phen (3), 4,7-diphenyl-1,10-phenanthroline, 4,7-Ph(2)-phen (4)). The X-ray crystal structure of complex 1 has been investigated. Upon photoexcitation, complexes 1-4 exhibit intense and long-lived emission in fluid solutions at 298 K and in low-temperature glass. The luminescence is assigned to a triplet intra-ligand ((3)IL) excited state associated with the pba(-) ligand, probably with mixing of some triplet metal-to-ligand charge-transfer ((3)MLCT) (dpi(Ir)-->pi*(pba(-))) character. Since each of these complexes possesses two aldehyde groups, which can react with the primary amine groups of biomolecules to form stable secondary amines after reductive amination, we have investigated the possibility of these complexes as novel luminescent cross-linkers for biological substrates.
3.Decreased hepatic ischemia-reperfusion injury by manganese-porphyrin complexes.
Wu TJ1, Khoo NH, Zhou F, Day BJ, Parks DA. Free Radic Res. 2007 Feb;41(2):127-34.
Reactive oxygen and nitrogen species have been implicated in ischemia-reperfusion (I/R) injury. Metalloporphyrins (MP) are stable catalytic antioxidants that can scavenge superoxide, hydrogen peroxide, peroxynitrite and lipid peroxyl radicals. Studies were conducted with three manganese-porphyrin (MnP) complexes with varying superoxide dimutase (SOD) and catalase catalytic activity to determine if the MnP attenuates I/R injury in isolated perfused mouse livers. The release of the hepatocellular enzymes alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) was maximal at 1 min reperfusion, decreased rapidly and increased gradually by 90 min. Manganese tetrakis-(N-ethyl-2 pyridyl) porphyrin (MnTE-2-PyP) decreased ALT, AST, LDH at 1-90 min reperfusion, while manganese tetrakis-(N-methyl-2 pyridyl) porphyrin (MnTM-2-PyP) and manganese tetrakis-(ethoxycarbonyl) porphyrin (MnTECP) decreased ALT and LDH from 5 to 90 min reperfusion.
4.Enantioselective synthesis of (2-pyridyl)alanines via catalytic hydrogenation and application to the synthesis of L-azatyrosine.
Adamczyk M1, Akireddy SR, Reddy RE. Org Lett. 2001 Oct 4;3(20):3157-9.
[reaction: see text] A novel method for the synthesis of (2-pyridyl)alanines 2a-b was developed by converting (2-pyridyl)dehydroamino acid derivatives 1a-b to the corresponding N-oxides 3a-b followed by asymmetric hydrogenation using (R,R)-[Rh(Et-DUPHOS)(COD)]BF(4) [(R,R)-6] catalyst and subsequent N-oxide reduction in 80-83% ee. This methodology was applied to the total synthesis of L-azatyrosine [(+)-12], an antitumor antibiotic, starting from (5-benzyloxy)-2-pyridylmethanol (7), in >96% enantiomeric purity.
